Volume 20, Issue 4 (Winter 2023)                   Sci J Iran Blood Transfus Organ 2023, 20(4): 298-311 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moradi V, Ranjbar A, Omidkhoda A, Ahmadbeigi N. In vitro comparison of cytotoxicity of CD19 CAR-CIK and CD19 CAR-T cells. Sci J Iran Blood Transfus Organ 2023; 20 (4) :298-311
URL: http://bloodjournal.ir/article-1-1510-en.html
In vitro comparison of cytotoxicity of CD19 CAR-CIK and CD19 CAR-T cells
V. Moradi * , A. Ranjbar , A. Omidkhoda , N. Ahmadbeigi
Keywords: Key words: Chimeric Antigen Receptors, T Cells, Cytokine-Induced Killer Cells, Graft-Versus-Host Disease
Full-Text [PDF 896 kb]   (484 Downloads)     |   Abstract (HTML)  (911 Views)
Full-Text:   (246 Views)



Sci J Iran Blood Transfus Organ 2023;20 (4): 298-311
Original Article
 
In vitro comparison of cytotoxicity of CD19 CAR-CIK
and CD19 CAR-T cells

Moradi V.1, Ranjbar A.2, Omidkhoda A.1, Ahmadbeigi N.2


1Hematology and Blood Transfusion Science Department. School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
2Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran


Abstract
Background and Objectives
Despite the success of CAR-T cells in the treatment of hematologic malignancies, the use of allogeneic sources of T lymphocytes to produce these cells is associated with risk of GvHD. Cytokine induced killer (CIK) cells are a population with a lower risk of GvHD. Therefore, CAR-CIK cells can be evaluated as a potential alternative for CAR-T cells.

Materials and Methods
In this experimental study, after isolation and culture of mononuclear cells isolated from the peripheral blood of two healthy donors, T and CIK cells are transduced with CD19 gene containing lentiviral vector. On the 16th day of culture, to compare the cytotoxicity of CAR-T and CAR-CIK cells, these cells were co-cultured with CD19+ K562 target cells, and the death rate among the target cells was measured using a lactate dehydrogenase release assay kit. Student T-test, Anova and post-hoc Tukey were used for statistical analysis using Graph Pad prism software 8. A p-value less than 0.05 was considered statistically significant.

Results
In both CAR-CIK and CAR-T cell, CAR receptor caused a significant increase in cytotoxicity. So that no significant difference was observed between the cytotoxicity of CAR-T cells (67.8% ± 1.7) and CAR-CIK (65.1% ± 1.8).

Conclusions 
CAR-CIK cells show a suitable in vitro cytotoxicity, so they can be considered as a potential alternative for CAR-T cells. However, more preclinical and clinical studies are needed to compare other effective dimensions in the function of these two cell types.

Key words: Chimeric Antigen Receptors, T Cells, Cytokine-Induced Killer Cells, Graft-Versus-Host Disease



Received:    5 Sep 2023
Accepted: 14 Nov 2023



Correspondence: Omidkhoda A., PhD of Hematology and Blood Transfusion. Associate Professor of  School of Allied Medical Sciences, Tehran University of Medical Sciences.
P.O.Box: 14177-44361, Tehran, Iran. Tel: (+9821) 82415227; Fax: (+9821) 88634118
E-mail: a-omidkhoda@tums.ac.ir
Correspondence: Ahmadbeigi N., PhD of Hematology and Blood Transfusion. Associate Professor of  Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences.
P.O.Box: 13135-14117, Tehran, Iran. Tel: (+9821) 82415227; Fax: (+9821) 8863411
E-mail: n-ahmadbeigi@tums.ac.ir


References:
  1. Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem 2022; 3(Suppl 1): 6-10.
  2. Cao X, Li W, Yu Y, Liu T, Zhou Y. China enters CAR-T cell therapy era. Innovation (Camb) 2021; 3(1): 100197.
  3. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021; 11(4): 69.
  4. Arabi F, Torabi-Rahvar M, Shariati A, Ahmadbeigi N, Naderi M. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Exp Cell Res 2018; 369(1): 1-10.
  5. Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev 2017; 4: 92-101.
  6. Choi G, Shin G, Bae S. Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int J Environ Res Public Health 2022; 19(19): 12366.
  7. Martinez-Cibrian N, Español-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V. Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. Front Immunol 2022; 13: 1005457.
  8. Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Front Immunol 2021; 12: 780442.
  9. Ren A, Tong X, Xu N, Zhang T, Zhou F, Zhu H. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines (Basel) 2023; 11(1): 165.
  10. Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 2018; 32(11): 2307-15.
  11. Liu DD, Hong WC, Qiu KY, Li XY, Liu Y, Zhu LW, et al. Umbilical cord blood: A promising source for allogeneic CAR-T cells. Front Oncol 2022; 12: 944248. 
  12. Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng 2023; 7(1): 24-37.
  13. Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, et al. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. Front Immunol 2021; 12: 780145.
  14. Muhammadnejad S, Monzavi SM, Torabi-Rahvar M, Sotoudeh M, Muhammadnejad A, Tavakoli-Shiraji S, et al. Efficacy of adoptively transferred allogeneic CIK cells on colorectal cancer: Augmentative antitumoral effects of GvHD. Int Immunopharmacol 2023; 114: 109446.
  15. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined       immunodeficiency.           J       Immunol 1994; 153(4): 1687-96.
  16. Drobyski WR, Majewski D, Ozker K, Hanson G. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J Immunol 1998; 161(5): 2610-9.
  17. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction  due  to  interferon gamma production. Blood 2001; 97(10): 2923-31.
  18. Ren X, Ma W, Lu H, Yuan L, An L, Wang X, et al. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive  malignancies.  Cancer   Immunol Immunother 2015; 64(12): 1517-29.
  19. Kiani J, Naderi M, Torabi-Rahvar M, Ranjbar A, Aghayan HR, Janzamin E, et al. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells. Arch Iran Med 2019; 22(1): 7-10.
  20. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012; 2012: 238924.
  21. Pizzitola I, Agostoni V, Cribioli E, Pule M, Rousseau R, Finney H, et al. in vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J Immunother. 2011; 34(6): 469-79.
  22. Marin   V,    Pizzitola   I,    Agostoni  V, Attianese GM, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010; 95(12): 2144-52.
  23. Hombach  AA,  Rappl  G,  Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation. Mol Ther 2013; 21(12): 2268-77.
  24. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, et al. in vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008; 112(6): 2563-74.
  25. Zuo S, Wen Y, Panha H, Dai G, Wang L, Ren X, et al. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers. Mol Immunol 2017; 85: 293-304.
  26. Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. Front Immunol 2022; 13: 936496.
  27. MacDonald A, Wu TC, Hung CF. Interleukin 2-Based Fusion Proteins for the Treatment of Cancer. J Immunol Res 2021; 2021: 7855808.
Type of Study: Research | Subject: Imunology
Published: 2023/12/31
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb